특발성 폐섬유증 치료 시장

The market for idiopathic pulmonary fibrosis treatment is anticipated to grow from US$ 6.56 billion in 2024 to US$ 14.10 billion by 2031, with an estimated CAGR of 12.0% during the period from 2025 to 2031.

Analyst Perspective:Idiopathic pulmonary fibrosis is a chronic disease that impacts the tissue surrounding the alveoli in the lungs. It occurs when lung tissues become stiff and thick for unknown reasons, leading to permanent scarring over time, which complicates breathing for patients. At present, there is no definitive cure for idiopathic pulmonary fibrosis. Treatments such as pulmonary rehabilitation, medications, and surgical options aim to slow lung damage and improve the quality of life for patients.

The rising incidence of idiopathic pulmonary fibrosis, coupled with an increasing number of smokers, is driving the demand for effective treatment options in the upcoming years. Ongoing research aimed at developing effective drugs for idiopathic pulmonary fibrosis is expected to further enhance market growth in the future. Additionally, healthcare spending is on the rise in both developed and emerging markets, which is likely to motivate manufacturers to focus on creating new and innovative products.

Market Overview:Fibrosis refers to the accumulation of connective tissue that can occur as part of the normal healing process or as a pathological condition. Idiopathic pulmonary fibrosis specifically affects the connective tissue in the lungs and alveoli (the air sacs in the lungs). This condition can lead to shortness of breath during routine activities that are not strenuous for healthy individuals. The expansion of the idiopathic pulmonary fibrosis treatment market is linked to the increasing prevalence of fibrotic conditions and a rise in smoking rates. Rapid advancements in research and development are expected to create growth opportunities for the idiopathic pulmonary fibrosis treatment market in the near future.

Strategic Insights

Market Driver:Increasing Incidence of Idiopathic Pulmonary Fibrosis Fuels Market Growth

As per the American Lung Association's data updated in November 2022, around 50,000 new cases of idiopathic pulmonary fibrosis are diagnosed annually in the US. Symptoms of this condition are more pronounced in individuals aged 50 to 70. An article published in the British Medical Journal in September 2022 indicated that the estimated prevalence of idiopathic pulmonary fibrosis in specialized care units in 2021 was 36.0 per 100,000. The number of patients suffering from idiopathic pulmonary fibrosis is rising globally due to common risk factors such as aging, obesity, hypertension, and family history, making it a significant socioeconomic burden. Consequently, the increasing patient population with idiopathic pulmonary fibrosis supports the growth of the fibrotic disease treatment market.

Segmental Analysis:The idiopathic pulmonary fibrosis treatment market is categorized by drug type into nintedanib, pirfenidone, and others. The nintedanib segment held a larger market share in 2022, while the others segment is projected to achieve a higher CAGR of 46.3% from 2022 to 2030. Pirfenidone and nintedanib are the most commonly prescribed medications for treating fibrotic diseases.

Regional Analysis:North America leads the global idiopathic pulmonary fibrosis treatment market, valued at US$ 2,362.95 million in 2022 and expected to reach US$ 5,527.28 million by 2030, with a projected CAGR of 11.2% during 2022-2030. The North American market is divided into the US, Canada, and Mexico. The increasing incidence of idiopathic pulmonary fibrosis and advancements in treatment technologies are beneficial for the market in North America. Product launches and strategic initiatives by key players also contribute to market growth. With the rise in research and development activities aimed at treating idiopathic pulmonary fibrosis, improved medications are being introduced, enhancing access to treatments for a broader patient base. Furthermore, extensive FDA approvals in the region encourage companies to launch technologically advanced products.

Europe, with its rising prevalence of idiopathic pulmonary fibrosis and high healthcare spending, holds the second-largest share in the global fibrotic disease treatment market. Germany is expected to lead the European idiopathic pulmonary fibrosis treatment market due to better access to advanced healthcare products and services.

The Asia Pacific region is anticipated to exhibit the fastest CAGR in the global idiopathic pulmonary fibrosis treatment market from 2022 to 2030. This projected growth is attributed to the widespread adoption of innovative technologies that yield accurate results in a significantly shorter timeframe. Healthcare sectors across the region are leveraging advancements in artificial intelligence, automation, and digital transformation, enhancing efficiency and productivity among medical professionals. The ongoing transformation across various industries strengthens businesses and economies in the Asia Pacific, positioning them as a rapidly developing hub with a dynamic and forward-thinking approach to sustainable growth.

Key Player Analysis:The analysis of the idiopathic pulmonary fibrosis treatment market includes key players such as Genentech, Inc. and Boehringer Ingelheim International GmbH.

Idiopathic Pulmonary Fibrosis Treatment Market Report Scope

Recent Developments:Companies in the idiopathic pulmonary fibrosis treatment market are actively pursuing both inorganic and organic strategies, such as mergers and acquisitions. Some recent developments include:

In May 2023, Boehringer Ingelheim began clinical development of BI 765423, a novel IL-11 inhibitor antibody. The Phase 1 study (NCT05658107) aims to assess its safety, tolerability, and pharmacokinetics in healthy volunteers. Preclinical studies have shown promising results for this anti-IL-11 drug in inhibiting and potentially reversing fibrosis in various fibrotic conditions.

In October 2022, Boehringer Ingelheim enrolled the first US patient in the FIBRONEER-IPF Phase III study evaluating BI 1015550, an experimental phosphodiesterase 4B (PDE4B) inhibitor designed for treating individuals with idiopathic pulmonary fibrosis. This study is part of the global FIBRONEER program, which includes two Phase III studies: FIBRONEER-IPF for idiopathic pulmonary fibrosis patients and FIBRONEER-ILD for adults with other progressive fibrosing interstitial lung diseases (ILDs).

In September 2022, Bellerophon Therapeutics, Inc. announced that the FDA accepted its application for reducing the trial size for the ongoing REBUILD Phase 3 registration trial of INOpulse, indicated for the treatment of fibrotic interstitial lung disease (LD).

In May 2022, ArisGlobal, a leader in drug safety solutions, acquired Boehringer Ingelheim's BRASS digital innovation. This acquisition allowed ArisGlobal to enhance its LifeSphere technology platform by integrating BRASS into LifeSphere Clarity, advancing pharmacovigilance and patient safety across the industry. Additionally, ArisGlobal has expanded its clinical diagnostics business presence globally, strengthening its position.

In March 2022, Bristol Myers Squibb announced the acquisition of Turning Point Therapeutics, Inc. for US$ 76.00 per share through a definitive merger agreement. This acquisition significantly bolstered Bristol Myers Squibb's global presence in the pharmaceutical market, enabling it to be more proactive in delivering innovations while expanding its portfolio of life-saving therapies and treatments.

Table Of Contents

1. Introduction

• 1.1 Scope of the Study
• 1.2 Market Definition, Assumptions and Limitations
• 1.3 Market Segmentation

2. Executive Summary

• 2.1 Key Insights
• 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Idiopathic Pulmonary Fibrosis Treatment Market Landscape

• 4.1 Overview
• 4.2 PEST Analysis
• 4.3 Ecosystem Analysis
  • 4.3.1 List of Vendors in the Value Chain

5. Idiopathic Pulmonary Fibrosis Treatment Market - Key Market Dynamics

• 5.1 Key Market Drivers
• 5.2 Key Market Restraints
• 5.3 Key Market Opportunities
• 5.4 Future Trends
• 5.5 Impact Analysis of Drivers and Restraints

6. Idiopathic Pulmonary Fibrosis Treatment Market - Global Market Analysis

• 6.1 Idiopathic Pulmonary Fibrosis Treatment - Global Market Overview
• 6.2 Idiopathic Pulmonary Fibrosis Treatment - Global Market and Forecast to 2030

7. Idiopathic Pulmonary Fibrosis Treatment Market - Revenue Analysis (USD Million) - By Drug Type, 2020-2030

• 7.1 Overview
• 7.2 Nintedanib
• 7.3 Pirfenidone
• 7.4 Others

8. Idiopathic Pulmonary Fibrosis Treatment Market - Revenue Analysis (USD Million) - By End User, 2020-2030

• 8.1 Overview
• 8.2 Hospitals Pharmacies
• 8.3 Retail Pharmacies
• 8.4 Online Pharmacies

9. Idiopathic Pulmonary Fibrosis Treatment Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

• 9.1 North America
  • 9.1.1 North America Idiopathic Pulmonary Fibrosis Treatment Market Overview
  • 9.1.2 North America Idiopathic Pulmonary Fibrosis Treatment Market Revenue and Forecasts to 2030
  • 9.1.3 North America Idiopathic Pulmonary Fibrosis Treatment Market Revenue and Forecasts and Analysis - By Drug Type
  • 9.1.4 North America Idiopathic Pulmonary Fibrosis Treatment Market Revenue and Forecasts and Analysis - By End User
  • 9.1.5 North America Idiopathic Pulmonary Fibrosis Treatment Market Revenue and Forecasts and Analysis - By Countries
    • 9.1.5.1 United States Idiopathic Pulmonary Fibrosis Treatment Market
      • 9.1.5.1.1 United States Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Type
      • 9.1.5.1.2 United States Idiopathic Pulmonary Fibrosis Treatment Market, by End User
    • 9.1.5.2 Canada Idiopathic Pulmonary Fibrosis Treatment Market
      • 9.1.5.2.1 Canada Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Type
      • 9.1.5.2.2 Canada Idiopathic Pulmonary Fibrosis Treatment Market, by End User
    • 9.1.5.3 Mexico Idiopathic Pulmonary Fibrosis Treatment Market
      • 9.1.5.3.1 Mexico Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Type
      • 9.1.5.3.2 Mexico Idiopathic Pulmonary Fibrosis Treatment Market, by End User
• 9.2 Europe
  • 9.2.1 Germany
  • 9.2.2 France
  • 9.2.3 Italy
  • 9.2.4 Spain
  • 9.2.5 United Kingdom
  • 9.2.6 Rest of Europe
• 9.3 Asia-Pacific
  • 9.3.1 Australia
  • 9.3.2 China
  • 9.3.3 India
  • 9.3.4 Japan
  • 9.3.5 South Korea
  • 9.3.6 Rest of Asia-Pacific
• 9.4 Middle East and Africa
  • 9.4.1 South Africa
  • 9.4.2 Saudi Arabia
  • 9.4.3 U.A.E
  • 9.4.4 Rest of Middle East and Africa
• 9.5 South and Central America
  • 9.5.1 Brazil
  • 9.5.2 Argentina
  • 9.5.3 Rest of South and Central America

10. Industry Landscape

• 10.1 Mergers and Acquisitions
• 10.2 Agreements, Collaborations, Joint Ventures
• 10.3 New Product Launches
• 10.4 Expansions and Other Strategic Developments

11. Competitive Landscape

• 11.1 Heat Map Analysis by Key Players
• 11.2 Company Positioning and Concentration

12. Idiopathic Pulmonary Fibrosis Treatment Market - Key Company Profiles

• 12.1 F. Hoffmann-La Roche Ltd
  • 12.1.1 Key Facts
  • 12.1.2 Business Description
  • 12.1.3 Products and Services
  • 12.1.4 Financial Overview
  • 12.1.5 SWOT Analysis
  • 12.1.6 Key Developments
• 12.2 Boehringer Ingelheim
• 12.3 AstraZeneca
• 12.4 Bristol Myers Squibb
• 12.5 Shionogi and Co. Ltd.
• 12.6 Cipla Ltd
• 12.7 Others

13. Appendix

• 13.1 Glossary
• 13.2 About The Insight Partners
• 13.3 Market Intelligence Cloud